OssDsign updates its strategy and establishes new financial ambitions to support growth, value creation and innovation

OssDsign AB (publ) (“OssDsign” or the “Company”) today provides details of its new strategy, ASCENT25, intended to accelerate growth, value creation and innovation of the company until 2025. The updated strategy and the new financial ambitions will be presented during a webcast today.The new strategy will broaden OssDsign from being a company focusing on the Craniomaxillofacial (CMF) market to participation across three orthopaedic market segments: · Craniomaxillofacial · Orthobiologics · Spine With a clear focus on execution, the new strategy ASCENT25 comprises five key